(NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Keith Gottesdiener, M.D., to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback